Bayer, Novartis Seek Broad Orphan Drug Exemption From HCR Annual Fees
Bayer and Novartis are among a number of companies pushing to ensure a broad interpretation of exemption for orphan drugs from the annual market-based fees that drug firms newly owe under the Affordable Care Act.
You may also be interested in...
IRS Annual Fee Rule For Brand Drug Manufacturers Clarifies Orphan Drug Exclusion, Part B Calculations
Policies outlined in the temporary rule will remain "applicable" until at least Aug. 15, 2014.
340B Orphan Drug Rule: Stakeholders Are Parsing ACA Statute – Should Some Indications Be Cheaper Than Others?
Health care institutions that benefit from the recent expansion of the 340B program are applauding the HHS Health Resources and Services Administration’s interpretation of an orphan drugs provision that allows more products to be available at a discount. But some others question whether it fits with the plain language of the statute.